+91-22-48913909The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis TATA India PHARMA & Healthcare Fund - G
Scheme Objective
CAGR return of 11.7% since its launch. Return for 2025 was -4.9% , 2024 was 40.4% and 2023 was 36.6% . NAV as on 19 Jun 26 ₹31.7427 ↑ 0.12 (0.38 %) Net Assets (AUM) as on 31 May 2026 ₹1,387 Cr. Launch Date 28 Dec 2015 Category Equity - Sectoral Rating Type Open Ended Fund Risk High AMC Tata Asset Management Limited Alpha Ratio -7.02 Expense Ratio 2.17 % Sharpe Ratio 0.144 Information Ratio -0.62 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 19 Jun 26 Duration Returns 1 Month -0.2% 3 Month 11.6% 6 Month 5.1% 1 Year 8.3% 3 Year 21.4% 5 Year 13.8% 10 Year 15 Year Since launch 11.7% Historical Annual Returns
Year Returns 2025 -4.9% 2024 40.4% 2023 36.6% 2022 -8% 2021 19.1% 2020 64.4% 2019 5.5% 2018 -2.6% 2017 4.7% Growth of 10k Over Years
Date Value 31 May 21 ₹10,000 31 May 22 ₹9,577 31 May 23 ₹10,225 31 May 24 ₹15,108 31 May 25 ₹17,655 31 May 26 ₹18,854 
Asset Allocation
Asset Class Value Cash 0.42% Equity 99.58% 
Sector Allocation
Sector Value Health Care 93.72% Basic Materials 5.19% Financial Services 0.67% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹131 Cr 723,130 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 6% ₹78 Cr 120,600 HealthCare Global Enterprises Ltd (Healthcare)
Equity, Since 31 Dec 18 | HCGMedical Care Facilities 5% ₹72 Cr 1,261,727 Abbott India Ltd (Healthcare)
Equity, Since 30 Sep 25 | ABBOTINDIADrug Manufacturers - Specialty & Generic 5% ₹71 Cr 27,953 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Jul 25 | MAXHEALTHMedical Care Facilities 5% ₹69 Cr 690,488
↑ 33,742 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | 500087Drug Manufacturers - Specialty & Generic 5% ₹67 Cr 512,754
↑ 150 Rainbow Childrens Medicare Ltd (Healthcare)
Equity, Since 31 Jul 25 | 543524Medical Care Facilities 4% ₹56 Cr 447,133 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSPMedical Care Facilities 4% ₹54 Cr 70,484 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKINDDrug Manufacturers - Specialty & Generic 4% ₹49 Cr 220,018
↑ 973 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDYDrug Manufacturers - Specialty & Generic 4% ₹49 Cr 373,464
↑ 35,868
Talk to our investment specialistFund Managers
Name Since Tenure Rajat Srivastava 16 Sep 24 1.71 Yr. Custodians
Company Address Deutsche Bank AG 1 Great Winchester Street Registrar & Transfer Agent
Computer Age Management Services Ltd Address New No.10, Old No.178,,Kodambakkam High Road,,Opp. Hotel Palmgrove,,Nungambakkam FAX 91-44-28283610 Email enq_L@camsonline.com Administrator Companies
Company Address Tata Mutual Fund 1903, B-Wing, Parinee Crescenzo,,G-Block, Bandra Kurla Complex, Bandra East Mumbai 400051 Auditors
Company Address Deloitte Haskins & Sells LLP 12, Dr. Annie Besant Road, Opp. Shiv Sagar Estate,,Worli M/s BSR & Co. KPMG House, Kamala Mills Compound,448 Senapati Bapat Marg,Lower Parel All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year TATA India Pharma & Healthcare Fund
Normal Dividend, Reinvestment ₹30.5283
↑ 0.12 4.98 % 8.13 % 21.34 % 13.75 % TATA India Pharma & Healthcare Fund
Normal Dividend, Payout ₹30.5283
↑ 0.12 4.98 % 8.13 % 21.34 % 13.75 % TATA India Pharma & Healthcare Fund
Growth ₹31.7427
↑ 0.12 5.12 % 8.28 % 21.4 % 13.78 % Data as on 19 Jun 26
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2026 Shepard Technologies Private Limited. All Rights Reserved